iSpecimen Inc. Cash Flow Statement
ISPC|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
iSpecimen Inc. used $8M in operating cash flow and negative free cash flow of $8M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.90 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$12.5M | -$11.1M | -$10.2M | -$9.0M | -$4.7M |
| Depreciation & Amortization | $2.3M | $2.1M | $22.4K | $45.4K | $44.8K |
| Operating Cash Flow | -$8.3M | -$5.8M | -$5.8M | -$10.7M | -$288.4K |
| Capital Expenditures | $31.5K | $19.5K | $215.5K | $2.5K | $426 |
| Free Cash Flow | -$8.3M | -$5.8M | -$6.0M | -$10.7M | -$288.8K |
| FCF Margin | -89.3% | -58.7% | -58.0% | -95.8% | -3.5% |